Clinical and laboratory features of the 6 patients used as a source of human polyclonal aPL (aPL-IgG) and specificity of mouse monoclonal antibodies
| Patient no. . | Age, y/sex . | aCL (> 80 GPL) . | LA . | Anti-β2GPI . | Complement activation* . | Clinical features . |
|---|---|---|---|---|---|---|
| 1 | 57/M | + | + | − | + | LN |
| 2 | 25/M | + | − | − | + | DVT |
| 3 | 55/F | + | − | + | + | CVA Pregnancy loss |
| 4 | 26/F | + | + | + | + | DVT LN |
| 5 | 48/M | + | + | − | + | CVAs |
| 6 | 50/F | + | + | + | +/− | Hepatic, renal, cardiac infarction; renal TMA; pregnancy loss |
| Mouse mAbs | ||||||
| FB1 | + | − | − | + | ||
| FC1 | − | − | + | − | ||
| FD1 | + | − | − | − |
| Patient no. . | Age, y/sex . | aCL (> 80 GPL) . | LA . | Anti-β2GPI . | Complement activation* . | Clinical features . |
|---|---|---|---|---|---|---|
| 1 | 57/M | + | + | − | + | LN |
| 2 | 25/M | + | − | − | + | DVT |
| 3 | 55/F | + | − | + | + | CVA Pregnancy loss |
| 4 | 26/F | + | + | + | + | DVT LN |
| 5 | 48/M | + | + | − | + | CVAs |
| 6 | 50/F | + | + | + | +/− | Hepatic, renal, cardiac infarction; renal TMA; pregnancy loss |
| Mouse mAbs | ||||||
| FB1 | + | − | − | + | ||
| FC1 | − | − | + | − | ||
| FD1 | + | − | − | − |
LA indicates lupus anticoagulant; LN, lupus nephritis; DVT, deep vein thrombosis; CVAs, cerebrovascular accidents; +, positive; and −, negative.
+ indicates a number of C3b positive cells higher than 10%; +/−, 5% to 10% of the cells were C3b positive; and −, less than 5% of the cells were C3b positive.